Andere Sprachen Centessa Pharmaceuticals plc

Aktien

A3CQ72

US1523091007

CNTA

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 20.06.2025			% 5 Tage	% 1. Jan.
12.43 ^USD	-1.97%		+0.40%	-25.79%

20.06.	Europäische Aktien als American Depositary Receipts am Freitag im Rückzug	MT
18.06.	Europäische Aktien als US-ADRs am Mittwoch leicht im Plus	MT

Andere Sprachen

European Equities Traded in the US as American Depositary Receipts Retreat Friday	20.06.
European Equities Traded in the US as American Depositary Receipts Edge Higher Wednesday	18.06.
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application for ORX142, a Novel Orexin Receptor 2 Agonist, Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year	17.06.
Sector Update: Health Care Stocks Retreat Late Afternoon	16.06.
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders	16.06.
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year	16.06.
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year	16.06.
Centessa Pharmaceuticals plc Announces Clearance of Investigational New Drug Application for ORX142	16.06.
Centessa Pharmaceuticals : CNTA SLEEP Ph2 Study Design Poster FINAL	11.06.
Centessa Pharmaceuticals : CNTA SLEEP Ph1 Encore Poster FINAL	11.06.
European Equities Traded in the US as American Depositary Receipts Rise Thursday	05.06.
European Equities Traded in the US as American Depositary Receipts Advance Wednesday	04.06.
Centessa Pharmaceuticals plc Appoints Raphael Deferiere as Chief Accounting Officer and Principal Accounting Officer, Effective as of May 27, 2025	29.05.
Centessa Pharmaceuticals Insider Sold Shares Worth $699,111, According to a Recent SEC Filing	20.05.
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	19.05.
Centessa Pharmaceuticals Posts Revenue, Q1 Net Loss Narrows	14.05.
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 License and Other Revenue of $15M	14.05.
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 Net Loss $0.20 a Share, vs. FactSet Est of $0.37 Loss	14.05.
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025	14.05.
Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2025	14.05.
Centessa Pharmaceuticals Insider Sold Shares Worth $681,576, According to a Recent SEC Filing	22.04.
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024	24.03.
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2024	24.03.
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting	06.03.
Centessa Pharmaceuticals Plc's Subsidiary Centessa Pharmaceuticals (UK) Limited Enters into a License Agreement with Genmab A/S	21.02.

Keine Ergebnisse zu dieser Suche

Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Centessa Pharmaceuticals plc

Aktien

A3CQ72

US1523091007

CNTA

Biotechnologie

Andere Sprachen

Filter